Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H9N2 Influenza Vaccine With and Without MF59 Adjuvant
NCT00133471Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2005
- Primary completion
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of influenza a/h9n2 vaccine in Influenza A virus H9N2 infection (H9N2), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2005; status: completed.
02
Drugs
influenza a/h9n2 vaccine
03
Conditions
Influenza A virus H9N2 infection (H9N2)
Beyond the preview
Go deeper on NCT00133471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133471.